| Project item | Indications | Research phase | Cooperation demands |
| NSS-21001 | Cancer cachexia | Preclinical candidate compound identified | License-out or co-development. |
| Cat. No. | Species | Product Description | Structure | Purity | Feature |
|---|---|---|---|---|---|
| CEA-C001 | Human | ClinMax™ Human Interleukin 6 (IL-6) Quantitative ELISA Kit | |||
| CRS-A005 | Human | Human Interleukin-6(IL-6) ELISA Kit | |||
| IL6-C5249 | Cynomolgus | Cynomolgus IL-6 Protein, His Tag (MALS verified) |  |
|
|
| IL6-H82Q9 | Human | Biotinylated Human IL-6 Protein, Avitag™,His Tag |  |
|
|
| IL6-M82Q7 | Mouse | Biotinylated Mouse IL-6 Protein, Avitag™,His Tag |  |
|
|
| IL6-M5245 | Mouse | Mouse IL-6 Protein, His Tag |  |
|
|
| IL6-H8218 | Human | Biotinylated Human IL-6 Protein, epitope tag free, ultra sensitivity (primary amine labeling) |  |
|
|
| IL6-H4218 | Human | ActiveMax® Human IL-6 Protein, Tag Free |  |
|
|
Biotinylated Human IL-6, epitope tag free, primary amine labeling (Cat. No. IL6-H8218) stimulates proliferation of TF-1 human erythroleukemic cell line. The EC50 for this effect is 0.2532-0.4489 ng/mL (Routinely tested).
Loaded Biotinylated Human IL-6, epitope tag free, primary amine labeling (Cat. No. IL6-H8218) on SA Biosensor, can bind Human IL-6 R alpha, His Tag (Cat. No. ILR-H4223) with an affinity constant of 45.9 nM as determined in BLI assay (ForteBio Octet Red96e) (Routinely tested).
| Name | Research Code | Research Phase | Company | First Brand Name | First Approved Country | First Indication | First Approved Company | First Approved Date | Indications | Clinical Trials |
|---|---|---|---|---|---|---|---|---|---|---|
| Siltuximab | cCLB-8; CNTO-328 | Approved | Johnson & Johnson | Sylvant | Mainland China | Multicentric Castleman's Disease (MCD) | Beigene (Beijing) Biotechnology Co Ltd | 2014-04-23 | Lung Diseases; Lung Neoplasms; Lymphoma, Non-Hodgkin; Castleman Disease; Colorectal Neoplasms; Neoplasms, Plasma Cell; Prostatic Neoplasms; Multicentric Castleman's Disease (MCD); Monoclonal Gammopathy of Undetermined Significance; Respiratory Distress Syndrome, Adult; Respiratory Tract Infections; Multiple Myeloma; Pancreatic Neoplasms; Myelodysplastic Syndromes; Smoldering Multiple Myeloma; Carcinoma, Renal Cell; Pneumonia; Head and Neck Neoplasms; Ovarian Neoplasms | Details |
| Thalidomide | NSC-66847; NSC-527179; K-17; VP-02 | Approved | Celgene Corp | Talizer, Thalidomide Celgene, Thalidomide Pharmion, Synovir, Thalomid, Thaled | Japan | Leprosy, Lepromatous | Fujimoto Pharmaceutical | 1982-01-01 | HIV Infections; Spondylitis, Ankylosing; Myelodysplastic Syndromes; Idiopathic Pulmonary Fibrosis; Multiple Myeloma; HIV Wasting Syndrome; Erythema Nodosum; Leprosy, Lepromatous; Carcinoma, Hepatocellular | Details |
| Pomalidomide | IMID-4047; CDC-394; CC-4047; IMiD-1 | Approved | Celgene Corp | Pomalyst, Imnovid, Actimid, Pomalyst/Imnovid, 安跃 | Mainland China | Multiple Myeloma | Jiangsu Chia Tai-Tianqing Pharmaceutical Co Ltd | 2013-02-08 | Sarcoma; Anemia, Sickle Cell; Leukemia, Lymphocytic, Chronic, B-Cell; Neoplasm Metastasis; Sarcoma, Kaposi; Lymphoma, Non-Hodgkin; Amyloidosis; Primary Myelofibrosis; Lymphoma, Follicular; Prostatic Neoplasms; Medulloblastoma; Central Nervous System Neoplasms; Lung Diseases, Interstitial; Multiple Myeloma; Hodgkin Disease; Lymphoma, Large B-Cell, Diffuse; Scleroderma, Systemic; Solid tumours; Lymphoma, B-Cell; Bone Marrow Neoplasms | Details |
| Luminol sodium | MP-1032 | Approved | Selvim, Metrio | Psoriasis; Immune System Diseases | null | 1997-01-01 | Coronavirus Disease 2019 (COVID-19); Immune System Diseases; Psoriasis | Details | ||
| Lenalidomide | IMID-5013; CDC-5013; CDC-501; CC-5013; IMiD-3; ENMD-0997 | Approved | Celgene Corp | Revimid (former Brand Name), 瑞复美, Revlimid, Leavdo | EU | Lymphoma, B-Cell, Marginal Zone; Lymphoma, Follicular | Celgene Europe Bv | 2005-12-27 | Lymphoma, Follicular; Complex Regional Pain Syndromes; Crohn Disease; Carcinoma, Non-Small-Cell Lung; Melanoma; Leukemia, Lymphocytic, Chronic, B-Cell; Neoplasm Metastasis; Waldenstrom Macroglobulinemia; Thrombocytopenia; Lymphoma, Non-Hodgkin; Lymphoma; Lymphoma, T-Cell; Radiculopathy; Reflex Sympathetic Dystrophy; Prostatic Neoplasms; Lymphoma, Mantle-Cell; Lymphoma, B-Cell, Marginal Zone; Multiple Myeloma; Smoldering Multiple Myeloma; Lymphoma, Large B-Cell, Diffuse; Blood Protein Disorders; Leukemia-Lymphoma, Adult T-Cell; Myelodysplastic Syndromes; Paraproteinemias; Anemia; HIV Infections; Lymphoma, B-Cell; Solid tumours; Lymphoma, T-Cell, Peripheral; Hematologic Diseases; Leukemia, Myeloid | Details |
| Name | Research Code | Research Phase | Company | Indications | Clinical Trials |
|---|---|---|---|---|---|
| MEDI-5117 | WBP-216; MEDI-5117 | Phase 1 Clinical | Wuxi Apptec Co Ltd, Medimmune | Arthritis, Rheumatoid | Details |
| Cis-urocanic acid | Cis-UCA; UCA-001; UCA-002 | Phase 2 Clinical | Herantis Pharma | Dry Eye Syndromes; Urinary Bladder Neoplasms; Xerophthalmia; Dermatitis, Atopic | Details |
| Monoclonal Antibody (Mab) sB24M | Phase 1 Clinical | Pyoderma Gangrenosum | Details | ||
| HL-2351 | GX-P4; HL-2351; rhIL-1Ra-hyFc | Phase 1 Clinical | Genexine Inc | Arthritis, Rheumatoid; Cryopyrin-Associated Periodic Syndromes | Details |
| FB-704A | FB-704; FB-704A | Phase 2 Clinical | Fountain Biopharma | Arthritis, Rheumatoid; Asthma | Details |
| Tocilizumab biosimilar (Mycenax Biotech) | Phase 1 Clinical | Mycenax Biotech Inc | Arthritis, Rheumatoid | Details | |
| Ensereptide | PXL-01 | Phase 3 Clinical | Promore Pharma | Tissue Adhesions; Post-surgical adhesions; Cicatrix | Details |
| EBI-031 | EBI-031 | Phase 1 Clinical | Sesen Bio | Diabetic macular oedema; Uveitis | Details |
| Anti-interleukin-6 receptor monoclonal antibody (Biocad) | Phase 2 Clinical | Biocad | Autoimmune Diseases | Details | |
| PF-04236921 | PF-4236921; PF-04236921 | Phase 2 Clinical | Pfizer Pharmaceuticals Ltd (China) | Arthritis, Rheumatoid; Lupus Erythematosus, Systemic; Crohn Disease | Details |
| Clazakizumab | ALD-518; ALD518-003; BMS-645429; BMS-945429 | Phase 3 Clinical | Alder Biopharmaceuticals | Anemia; Graft vs Host Disease; Arthritis, Rheumatoid; Fatigue; Rejection of organ transplantation; Arthritis, Psoriatic; Inflammation; Cachexia; Carcinoma, Non-Small-Cell Lung; Crohn Disease; Stomatitis | Details |
| Wogonin | Phase 1 Clinical | Shandong Buchang Pharmaceuticals Co Ltd, Hefei Cosource Medicine Technology, Daewoong Pharmaceutical Co Ltd, China Pharmaceutical University | Respiratory Tract Infections; Neoplasms | Details | |
| Gerilimzumab | GB-224; RYI-008; ARGX-109 | Phase 2 Clinical | Argenx Se | Arthritis, Rheumatoid | Details |
| Isomyosamine | MYMD-1 | Phase 2 Clinical | Mymd Pharmaceuticals Inc | Hashimoto Disease; Healthy Aging | Details |
| Sirukumab | BA-003; CNTO-136 | Phase 2 Clinical | Glaxosmithkline Plc, Janssen Global Services Llc | Giant Cell Arteritis; Depressive Disorder, Major; Arthritis, Rheumatoid; Lupus Erythematosus, Cutaneous; Coronavirus Disease 2019 (COVID-19); Polymyalgia Rheumatica; Lupus Nephritis; Lupus Erythematosus, Systemic; Asthma | Details |
| Olokizumab | CDP-6038; Anti-IL6-UCB | Phase 3 Clinical | Ucb | Coronavirus Disease 2019 (COVID-19); Arthritis, Rheumatoid; Arthritis; Crohn Disease | Details |
| Efprezimod alfa | CD24-Fc; HAS-CD24; CD24-Fc-IgG; MK-7110; MK7110 | Phase 3 Clinical | Oncoimmune | Leukemia; Hematopoietic stem cell transplantation (HSCT); HIV Infections; Graft vs Host Disease; Coronavirus Disease 2019 (COVID-19); Myelodysplastic Syndromes; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Dyslipidemias; Leukemia, Myeloid, Acute; Melanoma | Details |
| Ziltivekimab | COR-001 | Phase 3 Clinical | Astrazeneca Pharmaceutical Co Ltd | Anemia; Cardiovascular Diseases; Renal Insufficiency, Chronic; Inflammation | Details |
This web search service is supported by Google Inc.
A-Z
